vs
GDEV Inc.（GDEV）与RHYTHM PHARMACEUTICALS, INC.（RYTM）财务数据对比。点击上方公司名可切换其他公司
GDEV Inc.的季度营收约是RHYTHM PHARMACEUTICALS, INC.的2.0倍（$119.9M vs $60.1M），GDEV Inc.净利率更高（13.9% vs -92.6%，领先106.4%），RHYTHM PHARMACEUTICALS, INC.同比增速更快（83.8% vs 13.3%）
GDEV Inc.是一家游戏娱乐控股公司，在纳斯达克上市，总部位于塞浦路斯利马索尔。该公司前身为2014年成立的游戏公司Nexters，2023年6月改组为控股集团，是欧洲前五的独立移动游戏企业，旗下拥有Nexters Studio、Cubic Games、Royal Ark、Game Gears、Light Hour Games等工作室，分支机构分布在塞浦路斯、亚美尼亚、哈萨克斯坦等地。
Rhythm Pharmaceuticals是一家专注于罕见病领域的生物制药企业，主要开发和商业化针对罕见遗传性肥胖症的靶向疗法，覆盖POMC缺陷、LEPR缺陷、巴德-毕德氏综合征等适应症，服务北美、欧洲地区缺少有效治疗方案的患者群体。
GDEV vs RYTM — 直观对比
营收规模更大
GDEV
是对方的2.0倍
$60.1M
营收增速更快
RYTM
高出70.5%
13.3%
净利率更高
GDEV
高出106.4%
-92.6%
损益表 — Q2 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $119.9M | $60.1M |
| 净利润 | $16.6M | $-55.6M |
| 毛利率 | — | 88.1% |
| 营业利润率 | 15.5% | -87.1% |
| 净利率 | 13.9% | -92.6% |
| 营收同比 | 13.3% | 83.8% |
| 净利润同比 | 13.0% | — |
| 每股收益（稀释后） | $0.90 | $-0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GDEVRYTM
| Q1 26 | — | $60.1M | ||
| Q4 25 | — | $57.3M | ||
| Q3 25 | — | $51.3M | ||
| Q2 25 | $119.9M | $48.5M | ||
| Q1 25 | — | $32.7M | ||
| Q4 24 | — | $41.8M | ||
| Q3 24 | — | $33.3M | ||
| Q2 24 | $105.8M | $29.1M |
净利润GDEVRYTM
| Q1 26 | — | $-55.6M | ||
| Q4 25 | — | $-47.5M | ||
| Q3 25 | — | $-52.9M | ||
| Q2 25 | $16.6M | $-46.6M | ||
| Q1 25 | — | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | — | $-43.6M | ||
| Q2 24 | $14.7M | $-32.3M |
毛利率GDEVRYTM
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
营业利润率GDEVRYTM
| Q1 26 | — | -87.1% | ||
| Q4 25 | — | -82.2% | ||
| Q3 25 | — | -102.6% | ||
| Q2 25 | 15.5% | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | 14.4% | -139.2% |
净利率GDEVRYTM
| Q1 26 | — | -92.6% | ||
| Q4 25 | — | -83.0% | ||
| Q3 25 | — | -103.1% | ||
| Q2 25 | 13.9% | -96.1% | ||
| Q1 25 | — | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | — | -131.2% | ||
| Q2 24 | 13.9% | -110.9% |
每股收益（稀释后）GDEVRYTM
| Q1 26 | — | $-0.83 | ||
| Q4 25 | — | $-0.73 | ||
| Q3 25 | — | $-0.82 | ||
| Q2 25 | $0.90 | $-0.75 | ||
| Q1 25 | — | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.73 | ||
| Q2 24 | $0.81 | $-0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $340.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-129.4M | $122.9M |
| 总资产 | $210.2M | $442.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GDEVRYTM
| Q1 26 | — | $340.6M | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | $41.6M | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | $50.8M | $319.1M |
股东权益GDEVRYTM
| Q1 26 | — | $122.9M | ||
| Q4 25 | — | $139.1M | ||
| Q3 25 | — | $148.8M | ||
| Q2 25 | $-129.4M | $-11.9M | ||
| Q1 25 | — | $18.9M | ||
| Q4 24 | — | $21.7M | ||
| Q3 24 | — | $11.2M | ||
| Q2 24 | $-118.7M | $39.3M |
总资产GDEVRYTM
| Q1 26 | — | $442.3M | ||
| Q4 25 | — | $480.2M | ||
| Q3 25 | — | $506.9M | ||
| Q2 25 | $210.2M | $372.7M | ||
| Q1 25 | — | $386.7M | ||
| Q4 24 | — | $392.3M | ||
| Q3 24 | — | $363.6M | ||
| Q2 24 | $282.8M | $381.8M |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
